+
  • 67f39da810174.jpg

13-valent pneumococcal polysaccharide conjugate vaccine


The world’s first 13-valent pneumococcal polysaccharide conjugate vaccine with a dual carrier system, a blockbuster vaccine category that enjoys global success.

400 189 9806

For more product details, please contact our product experts. We look forward to your call.

Product Description

Drug name

13-valent pneumococcal polysaccharide conjugate vaccine

13-Valent Pneumococcal Polysaccharide Conjugate Vaccine

Target population for vaccination

Infants and children aged 6 weeks to 5 years (before their sixth birthday)

Functions and Applications

Following vaccination with this product, the body’s immune response is stimulated, providing protection against infectious diseases caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.

Related products



acellular diphtheria–tetanus–pertussis and Haemophilus influenzae type b combination vaccine

Recombinant Hepatitis B Vaccine (Saccharomyces cerevisiae) (10 μg)

Live attenuated varicella vaccine

Lyophilized Haemophilus influenzae type b conjugate vaccine

Measles–rubella combined live attenuated vaccine

Adsorbed acellular diphtheria–tetanus–pertussis combined vaccine

Sabin-strain inactivated poliovirus vaccine (Vero cell)